Le séminaire avait pour sujet les crises sanitaires récentes. Face aux effets dévastateurs de peurs irraisonnées, comment gérer la communication? Louis Orenga, qui fait face à ces défis depuis de nombreuses années, témoignait de son expérience et des pistes pour sortir des ornières actuelles.

Les meilleurs experts des laboratoires et CROs français et étrangers vous aideront à évaluer la performance de vos Essais Cliniques. Sécuriser vos dispositifs et augmenter la performance réglementaires de vos organisations face aux toutes dernières avancées.

Biomarker Discovery and Validation: Challenges and Solutions

It discuses the cutting-edge solutions in the application of biomarkers for drug discovery and personalised medicine.

Biomarker Discovery and Validation: Challenges and Solutions

It discuses the cutting-edge solutions in the application of biomarkers for drug discovery and personalised medicine.

Biomarker Discovery and Validation: Challenges and Solutions

It discuses the cutting-edge solutions in the application of biomarkers for drug discovery and personalised medicine.

Biomarker Discovery and Validation: Challenges and Solutions

It discuses the cutting-edge solutions in the application of biomarkers for drug discovery and personalised medicine.

It focuses on future developments and changes in private cancer services. This will provide an excellent opportunity to listen to a distinguished panel of speakers who will address the challenges and opportunities for the role of private medical insurance.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.

The Synthetic Biology in Pharma Conference 2010

The conference focused on recent advances in the application of synthetic biology technologies in the fields of biopharmaceuticals and small-molecule therapeutics to identify future high-potential, high-value projects in the pharmaceutical product pipeline.